News & Media

Recent updates from Arcutis.

October 6, 2023 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

October 5, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 27, 2023

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

September 25, 2023

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

September 19, 2023

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

September 15, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2023

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

September 7, 2023

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

September 5, 2023

Arcutis to Present at Upcoming Investor Conference

August 31, 2023

Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report

August 29, 2023

Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%

August 18, 2023

Arcutis Appoints Interim Chief Financial Officer (CFO)

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download